Xenon Pharmaceuticals Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

XENE$41.39+2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity

(Expressed in thousands of U.S. dollars except share amounts)

Common shares · Additionalpaid-incapital · Accumulateddeficit · Accumulatedother comprehensiveincome (loss) · Totalshareholders'equity
Shares · Amount
Balance as of December 31, 2024	76,416,086	$1,456,836	$199,149	$(899,470)	$(1,612)	$754,903
Net loss for the period	—	—	—	(65,047)	—	(65,047)
Stock-based compensation expense	—	—	12,174	—	—	12,174
Issuance of common shares pursuant to equity incentive plans	170,273	4,014	(2,863)	—	—	1,151
Other comprehensive income	—	—	—	—	776	776
Balance as of March 31, 2025	76,586,359	$1,460,850	$208,460	$(964,517)	$(836)	$703,957

Balance as of December 31, 2025	80,010,790	$1,598,571	$228,234	$(1,245,380)	$335	$581,760
Net loss for the period	—	—	—	(102,302)	—	(102,302)
Issuance of common shares and pre-funded warrants, net	15,370,962	790,198	47,328	—	—	837,526
Exercise of pre-funded warrants	118,980	3,296	(3,296)	—	—	—
Stock-based compensation expense	—	—	16,894	—	—	16,894
Issuance of common shares pursuant to equity incentive plans	1,123,391	29,768	(24,281)	—	—	5,487
Other comprehensive loss	—	—	—	—	(1,546)	(1,546)
Balance as of March 31, 2026	96,624,123	$2,421,833	$264,879	$(1,347,682)	$(1,211)	$1,337,819

-5-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.